ARA290.
About ARA290
ARA290 is studied in tissue regeneration and repair research, including cell and animal models. ARA-290 selectively binds the heterodimeric 'innate repair receptor' (EPO receptor + beta-common receptor/CD131) rather than the classical homodimeric EPO receptor that drives erythropoiesis, decoupling EPO's tissue-protective signaling from its blood-cell-stimulating activity.
Research Application
Studied for neuropathic pain and small-fiber neuropathy (especially sarcoidosis-associated), diabetic neuropathy and metabolic control, and more broadly as a tissue-protective, anti-inflammatory research compound.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
Studies on regenerative peptides are mostly derived from cell culture and animal models; comprehensive clinical data is typically still limited.
- Brines M, et al. Proc Natl Acad Sci U S A. 2008;105(31):10925–10930. PMID 18676614
- Heij L, et al. Mol Med. 2012;18(1):1430–1436. PMID 23168581
- Brines M, et al. Mol Med. 2015;20:658–666. PMID 25387363
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Similar Peptides
Question about ARA290?
We reply personally – via email or Telegram.